Plus Therapeutics Presents Positive Respect-LM Trial Results Of Reyobiq In Leptomeningeal Metastases
ReutersAug 18, 2025 2:15 PM
Aug 18 (Reuters) - Plus Therapeutics Inc PSTV.O:
PLUS THERAPEUTICS PRESENTS POSITIVE RESPECT-LM CLINICAL TRIAL RESULTS OF REYOBIQ™ IN LEPTOMENINGEAL METASTASES
PLUS THERAPEUTICS INC - NO DOSE LIMITING TOXICITIES OBSERVED IN TRIAL
PLUS THERAPEUTICS INC - REYOBIQ SHOWS CLINICAL BENEFIT RATE OVER 75%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Circle’s Next Chapter: Not Just Stablecoins, But a Payments Network
TradingKey - Stablecoins are meeting real-world demand, especially in emerging markets where payment systems are oftenfragmented, access to the traditional banking system is limited, or capital controls restrict seamless global flows.TradingKey
Sat, Sep 20
What is BNB? Can CZ's Return to Binance Propel It to $2700?
It’s also worth noting that 2028 marks Bitcoin’s fifth halving — a historically bullish catalyst. If past cycles repeat, BNB could ride the wave to new highs. Considering macroeconomic trends, supply dynamics, CZ’s potential return, and the next bull market, Standard Chartered’s target seems increasTradingKey
Fri, Sep 19
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilizeTradingKey
Fri, Sep 12
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.TradingKey
Wed, Jul 16
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
Tradingkey
